NCT00665990View on ClinicalTrials.gov

Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
Refractory Solid TumorsLeukemia
Interventions
DRUG

Bevacizumab

Bevacizumab starting dose of 5 mg/kg every 3 weeks increasing in combination with Sorafenib and Cyclophosphamide until maximum tolerated dose

DRUG

Sorafenib

Sorafenib 90 mg/m2 PO every 12 hours increasing in combination with Bevacizumab and Cyclophosphamide until maximum tolerated dose

DRUG

Cyclophosphamide

Cyclophosphamide 50 mg/m2 PO once daily increasing in combination with Bevacizumab and Sorafenib until maximum tolerated dose

Trial Locations (1)

38105

St. Jude Children's Research Hospital, Memphis

All Listed Sponsors
lead

St. Jude Children's Research Hospital

OTHER

NCT00665990 - Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia | Biotech Hunter | Biotech Hunter